Zanamivir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zanamivir" in English language version.

refsWebsite

Global rank English rank

21nih.gov

4^th place

14doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

5web.archive.org

1^st place

4fda.gov

447^th place

338^th place

3harvard.edu

18^th place

17^th place

2cdc.gov

218^th place

212^th place

2csiro.au

4,114^th place

3,147^th place

1europa.eu

68^th place

117^th place

1selleckchem.com

low place

1rsc.org

2,020^th place

1,872^nd place

1worldcat.org

5^th place

cdc.gov

"2008-2009 Influenza Season Week 32 ending August 15, 2009". Flu Activity & Surveillance. Centers for Disease Control and Prevention (CDC). 21 August 2009.
"Influenza Antiviral Medications: Summary for Clinicians". CDC. 11 May 2018. Retrieved 21 April 2014.

csiro.au

csiropedia.csiro.au

"Colman, Peter Malcolm - CSIROpedia". Archived from the original on 4 October 2013. Retrieved 2 October 2013.
"Varghese, Joseph Noozhumurry - CSIROpedia". Archived from the original on 5 October 2013. Retrieved 2 October 2013.

doi.org

Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLOS ONE. 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.
Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. (June 2013). "Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance". Lancet. 381 (9885): 2273–2279. doi:10.1016/S0140-6736(13)61125-3. PMID 23726392. S2CID 7537862.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. (April 2014). "Neuraminidase inhibitors for preventing and treating influenza in adults and children". The Cochrane Database of Systematic Reviews. 2014 (4): CD008965. doi:10.1002/14651858.CD008965.pub4. PMC 6464969. PMID 24718923.
Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (April 2014). "Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments". BMJ. 348 (apr09 2): g2547. doi:10.1136/bmj.g2547. PMC 3981976. PMID 24811412.
Wang K, Shun-Shin M, Gill P, Perera R, Harnden A (April 2012). "Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)". The Cochrane Database of Systematic Reviews. 2012 (4): CD002744. doi:10.1002/14651858.CD002744.pub4. PMC 6599832. PMID 22513907.
Thorlund K, Awad T, Boivin G, Thabane L (May 2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134. PMC 3123567. PMID 21592407.
Hayden FG (December 2001). "Perspectives on antiviral use during pandemic influenza". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 356 (1416): 1877–1884. doi:10.1098/rstb.2001.1007. PMC 1088564. PMID 11779387.
Freund B, Gravenstein S, Elliott M, Miller I (October 1999). "Zanamivir: a review of clinical safety". Drug Safety. 21 (4): 267–281. doi:10.2165/00002018-199921040-00003. PMID 10514019. S2CID 25945928.
Cyranoski D (September 2005). "Threat of pandemic brings flu drug back to life". Nature Medicine. 11 (9): 909. doi:10.1038/nm0905-909. PMID 16145557.
Moscona A (September 2005). "Neuraminidase inhibitors for influenza". The New England Journal of Medicine. 353 (13): 1363–1373. doi:10.1056/NEJMra050740. PMID 16192481. S2CID 17162678.
Varghese JN, Laver WG, Colman PM (1983). "Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution". Nature. 303 (5912): 35–40. Bibcode:1983Natur.303...35V. doi:10.1038/303035a0. PMID 6843658. S2CID 4363648.
Meindl P, Bodo G, Palese P, Schulman J, Tuppy H (April 1974). "Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid". Virology. 58 (2): 457–463. doi:10.1016/0042-6822(74)90080-4. PMID 4362431.
von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. (June 1993). "Rational design of potent sialidase-based inhibitors of influenza virus replication". Nature. 363 (6428): 418–423. Bibcode:1993Natur.363..418V. doi:10.1038/363418a0. PMID 8502295. S2CID 4359333.
Cohen D, Carter P (June 2010). "Conflicts of interest. WHO and the pandemic flu "conspiracies"". BMJ. 340 (jun03 4): c2912. doi:10.1136/bmj.c2912. PMID 20525679. S2CID 35959611.

europa.eu

ema.europa.eu

"List of nationally authorised medicinal products" (PDF). European Medicines Agency.

fda.gov

"FDA Approves a Second Drug for the Prevention of Influenza A and B in Adults and Children FDA press release March 29, 2006". FDA. Archived from the original on 6 March 2010. Retrieved 16 December 2019.
"FDA Approves a Second Drug for the Prevention of Influenza A and B in Adults and Children". FDA press release.
"Safe and Appropriate Use of Influenza Drugs". Public Health Advisories (Drugs). U.S. Food and Drug Administration (FDA). 30 April 2009. Archived from the original on 4 November 2009. Retrieved 11 November 2009.
"Relenza (zanamivir) Inhalation Powder". Food and Drug Administration. Archived from the original on 12 October 2009.

harvard.edu

ui.adsabs.harvard.edu

Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLOS ONE. 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.
Varghese JN, Laver WG, Colman PM (1983). "Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution". Nature. 303 (5912): 35–40. Bibcode:1983Natur.303...35V. doi:10.1038/303035a0. PMID 6843658. S2CID 4363648.
von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. (June 1993). "Rational design of potent sialidase-based inhibitors of influenza virus replication". Nature. 363 (6428): 418–423. Bibcode:1993Natur.363..418V. doi:10.1038/363418a0. PMID 8502295. S2CID 4359333.

nih.gov

pubmed.ncbi.nlm.nih.gov

Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLOS ONE. 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.
Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. (June 2013). "Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance". Lancet. 381 (9885): 2273–2279. doi:10.1016/S0140-6736(13)61125-3. PMID 23726392. S2CID 7537862.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. (April 2014). "Neuraminidase inhibitors for preventing and treating influenza in adults and children". The Cochrane Database of Systematic Reviews. 2014 (4): CD008965. doi:10.1002/14651858.CD008965.pub4. PMC 6464969. PMID 24718923.
Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (April 2014). "Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments". BMJ. 348 (apr09 2): g2547. doi:10.1136/bmj.g2547. PMC 3981976. PMID 24811412.
Wang K, Shun-Shin M, Gill P, Perera R, Harnden A (April 2012). "Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)". The Cochrane Database of Systematic Reviews. 2012 (4): CD002744. doi:10.1002/14651858.CD002744.pub4. PMC 6599832. PMID 22513907.
Thorlund K, Awad T, Boivin G, Thabane L (May 2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134. PMC 3123567. PMID 21592407.
Hayden FG (December 2001). "Perspectives on antiviral use during pandemic influenza". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 356 (1416): 1877–1884. doi:10.1098/rstb.2001.1007. PMC 1088564. PMID 11779387.
Freund B, Gravenstein S, Elliott M, Miller I (October 1999). "Zanamivir: a review of clinical safety". Drug Safety. 21 (4): 267–281. doi:10.2165/00002018-199921040-00003. PMID 10514019. S2CID 25945928.
Cyranoski D (September 2005). "Threat of pandemic brings flu drug back to life". Nature Medicine. 11 (9): 909. doi:10.1038/nm0905-909. PMID 16145557.
Moscona A (September 2005). "Neuraminidase inhibitors for influenza". The New England Journal of Medicine. 353 (13): 1363–1373. doi:10.1056/NEJMra050740. PMID 16192481. S2CID 17162678.
Varghese JN, Laver WG, Colman PM (1983). "Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution". Nature. 303 (5912): 35–40. Bibcode:1983Natur.303...35V. doi:10.1038/303035a0. PMID 6843658. S2CID 4363648.
Meindl P, Bodo G, Palese P, Schulman J, Tuppy H (April 1974). "Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid". Virology. 58 (2): 457–463. doi:10.1016/0042-6822(74)90080-4. PMID 4362431.
von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. (June 1993). "Rational design of potent sialidase-based inhibitors of influenza virus replication". Nature. 363 (6428): 418–423. Bibcode:1993Natur.363..418V. doi:10.1038/363418a0. PMID 8502295. S2CID 4359333.
Cohen D, Carter P (June 2010). "Conflicts of interest. WHO and the pandemic flu "conspiracies"". BMJ. 340 (jun03 4): c2912. doi:10.1136/bmj.c2912. PMID 20525679. S2CID 35959611.

ncbi.nlm.nih.gov

Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLOS ONE. 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. (April 2014). "Neuraminidase inhibitors for preventing and treating influenza in adults and children". The Cochrane Database of Systematic Reviews. 2014 (4): CD008965. doi:10.1002/14651858.CD008965.pub4. PMC 6464969. PMID 24718923.
Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (April 2014). "Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments". BMJ. 348 (apr09 2): g2547. doi:10.1136/bmj.g2547. PMC 3981976. PMID 24811412.
Wang K, Shun-Shin M, Gill P, Perera R, Harnden A (April 2012). "Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)". The Cochrane Database of Systematic Reviews. 2012 (4): CD002744. doi:10.1002/14651858.CD002744.pub4. PMC 6599832. PMID 22513907.
Thorlund K, Awad T, Boivin G, Thabane L (May 2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134. PMC 3123567. PMID 21592407.
Hayden FG (December 2001). "Perspectives on antiviral use during pandemic influenza". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 356 (1416): 1877–1884. doi:10.1098/rstb.2001.1007. PMC 1088564. PMID 11779387.

dailymed.nlm.nih.gov

"Relenza- zanamivir powder". DailyMed. 19 October 2021. Retrieved 30 September 2022.

rsc.org

eic.rsc.org

Laver G (1 March 2007). "Flu drugs - pathway to discovery". Education in Chemistry. Vol. 44, no. 2. Royal Society of Chemistry. pp. 48–52. ISSN 0013-1350. Retrieved 19 June 2018.

selleckchem.com

Zanamivir, 2023

semanticscholar.org

api.semanticscholar.org

Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. (June 2013). "Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance". Lancet. 381 (9885): 2273–2279. doi:10.1016/S0140-6736(13)61125-3. PMID 23726392. S2CID 7537862.
Freund B, Gravenstein S, Elliott M, Miller I (October 1999). "Zanamivir: a review of clinical safety". Drug Safety. 21 (4): 267–281. doi:10.2165/00002018-199921040-00003. PMID 10514019. S2CID 25945928.
Moscona A (September 2005). "Neuraminidase inhibitors for influenza". The New England Journal of Medicine. 353 (13): 1363–1373. doi:10.1056/NEJMra050740. PMID 16192481. S2CID 17162678.
Varghese JN, Laver WG, Colman PM (1983). "Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution". Nature. 303 (5912): 35–40. Bibcode:1983Natur.303...35V. doi:10.1038/303035a0. PMID 6843658. S2CID 4363648.
von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. (June 1993). "Rational design of potent sialidase-based inhibitors of influenza virus replication". Nature. 363 (6428): 418–423. Bibcode:1993Natur.363..418V. doi:10.1038/363418a0. PMID 8502295. S2CID 4359333.
Cohen D, Carter P (June 2010). "Conflicts of interest. WHO and the pandemic flu "conspiracies"". BMJ. 340 (jun03 4): c2912. doi:10.1136/bmj.c2912. PMID 20525679. S2CID 35959611.

web.archive.org

"FDA Approves a Second Drug for the Prevention of Influenza A and B in Adults and Children FDA press release March 29, 2006". FDA. Archived from the original on 6 March 2010. Retrieved 16 December 2019.
"Safe and Appropriate Use of Influenza Drugs". Public Health Advisories (Drugs). U.S. Food and Drug Administration (FDA). 30 April 2009. Archived from the original on 4 November 2009. Retrieved 11 November 2009.
"Relenza (zanamivir) Inhalation Powder". Food and Drug Administration. Archived from the original on 12 October 2009.
"Colman, Peter Malcolm - CSIROpedia". Archived from the original on 4 October 2013. Retrieved 2 October 2013.
"Varghese, Joseph Noozhumurry - CSIROpedia". Archived from the original on 5 October 2013. Retrieved 2 October 2013.

worldcat.org

Laver G (1 March 2007). "Flu drugs - pathway to discovery". Education in Chemistry. Vol. 44, no. 2. Royal Society of Chemistry. pp. 48–52. ISSN 0013-1350. Retrieved 19 June 2018.